【摘要】 目的:观察紫杉醇与5-氟尿嘧啶分别联合奈达铂治疗晚期鼻咽癌(NPC)的临床疗效及安全性。方法:将42例晚期NPC患者按随机数字表法分为观察组和对照组,各21例。两组患者均同步进行放疗。与此同时,观察组患者化疗方案为紫杉醇135mg/m~2,d1,联合奈达铂80 mg/m~2,d2~4;对照组患者化疗方案为5-氟尿嘧啶500 mg/m~2,d1~5,联合奈达铂80 mg/m~2,d1~3。3周为1个疗程,两组患者均治疗2个疗程。观察两组患者临床疗效、生存率及不良反应。结果:观察组患者总有效率为95.2%,与对照组的90.5%比较,差异无统计学意义(P>0.05);观察组患者3年总生存率和无进展期生存率分别为81.0%和71.4%,对照组分别为76.2%和66.6%,组间比较差异均无统计学意义(P>0.05)。观察组患者恶心、呕吐发生率明显低于对照组,口腔黏膜炎症发生率明显高于对照组,差异有统计学意义(P<0.05)。结论:紫杉醇与5-氟尿嘧啶分别联合奈达铂治疗晚期NPC疗效相当,治疗中应严密监测患者不良反应并及时给予对症处理。更多还原

【Abstract】 OBJECTIVE: To observe clinical efficacy and safety of paclitaxel or 5-fluorouracil combined with nadaplatin in the treatment of advanced nasopharyngeal carcinoma(NPC). METHODS: 42 patients with advanced NPC were randomly divided into observation group and control group(n=21). 2 groups of patients were treated with radiotherapy. Observation group received chemotherapy of paclitaxel(135 mg/m~2,d1)and nedaplatin(80 mg/m~2,d 2-4);control group received chemotherapy of 5-fluorouracil(500 mg/m~2,d1-5)and nedaplatin(80 mg/m~2,d1-3);a treatment course lasted for 3 weeks,and both groups received 2 courses of treatment. Clinical efficacy, survival rate and ADR were observed in 2 groups. RESULTS:The overall response rate was 95.2%in observation group and 90.5% in control group,with no significant difference between 2 groups(P>0.05). The 3-year overall survival rate and progression-free survival rate were 81.0% and 71.4% in observation group and 76.2% and 66.6% in control group,with no significant difference(P>0.05). The incidence of nausea and vomiting in observation group were lower than in control group,while the incidence of oral mucosa inflammation was higher than control group,with statistical significance(P<0.05).CONCLUSIONS:The chemoradiotherapy of paclitaxel or 5-fluorouracil combined with nadaplatin have similar therapeutic efficacy for advanced NPC. ADR by chemoradiotherapy should be monitored closely and treated timely.更多还原